IO Biotech

IO Biotech FCF/Debt

Delisted·Sep 22, 2026

The Free Cash Flow to Debt Ratio of IO Biotech (IOBT) as of Nov 20, 2026 is -4,302.40 %. In the previous year, Free Cash Flow to Debt Ratio was -2,889.33 % — a change of 48.91% (lower).

FCF/Debt

-4,302.40 %

YoY

48.91%

Last updated:

Free Cash Flow to Debt Ratio of IO Biotech is 2024 -4,302.40 % . Free Cash Flow to Debt Ratio of IO Biotech was 2023 -2,889.33 % . It decreases by 48.91% lower compared to the previous year.

The IO Biotech FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-104.40 USD
Jan 1, 2022
-2,165.56 USD
Jan 1, 2023
-2,889.33 USD
Jan 1, 2024
-4,302.40 USD
The IO Biotech FCF/Debt history
YEARFCF/DebtYoY
-4,302.40 %+48.91%
-2,889.33 %+33.42%
-2,165.56 %+1,974.33%
-104.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

Free Cash Flow to Debt Ratio of IO Biotech is -4,302.40 % in 2024.

Free Cash Flow to Debt Ratio of IO Biotech changed from -2,889.33 % to -4,302.40 %, representing a 48.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio IO Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's IO Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IO Biotech

All Key Metrics — IO Biotech